Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastat

被引:41
作者
Burke, F
East, N
Upton, C
Patel, K
Balkwill, FR
机构
[1] IMPERIAL CANC RES FUND,DEPT HISTOPATHOL,LONDON WC2A 3PX,ENGLAND
[2] IMPERIAL CANC RES FUND,CLARE HALL LABS,LONDON WC2A 3PX,ENGLAND
[3] IMPERIAL CANC RES FUND,DEPT ELECTRON MICROSCOPY,LONDON WC2A 3PX,ENGLAND
关键词
IFN-gamma; ovarian cancer; animal model; batimastat; apoptosis;
D O I
10.1016/S0959-8049(97)88065-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Locoregional human IFN-gamma may have activity against refractory ovarian cancer. We investigated this further in an ovarian cancer xenograft model. Administered at clinically relevant doses, intraperitoneal IFN-gamma prolonged the survival of mice bearing multiple established peritoneal tumours, with optimal treatment giving a 3-6-fold increase in median survival time. Daily dosing, which was superior to intermittent treatment, decreased DNA synthesis and induced apoptosis in tumour cells with maximal effects after 7-21 days treatment. This was preceded by an increase in p53 protein at 48 h. The effect of IFN-gamma was not enhanced by sequential treatment with carboplatin. However, the matrix metalloprotease inhibitor, batimastat, further incrased mouse survival when given after IFN-gamma. Thus IFN-gamma is cytotoxic to ovarian epithelial cells in vivo and intensive locoregional dosing over short periods is effective. Sequential administration of novel agents that perturb the host/tumour relationship may be of benefit. (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:1114 / 1121
页数:8
相关论文
共 35 条
[1]  
ARENDS MJ, 1990, AM J PATHOL, V136, P593
[2]   LOW-DOSE GAMMA-INTERFERON THERAPY IS INEFFECTIVE IN RENAL-CELL CARCINOMA PATIENTS WITH LARGE TUMOR BURDEN [J].
AULITZKY, WE ;
LERCHE, J ;
THEWS, A ;
LUTTICHAU, I ;
JACOBI, N ;
HEROLD, M ;
AULITZKY, W ;
PESCHEL, C ;
STOCKLE, M ;
STEINBACH, F ;
HUBER, C .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (07) :940-945
[3]   ACUTE EFFECTS OF SINGLE DOSES OF RECOMBINANT INTERFERON-GAMMA ON BLOOD-CELL COUNTS AND LYMPHOCYTE SUBSETS IN PATIENTS WITH ADVANCED RENAL-CELL CANCER [J].
AULITZKY, WE ;
AULITZKY, W ;
GASTL, G ;
LANSKE, B ;
REITTER, J ;
FRICK, J ;
TILG, H ;
BERGER, M ;
HEROLD, M ;
HUBER, C .
JOURNAL OF INTERFERON RESEARCH, 1989, 9 (04) :425-433
[4]  
BALKWILL FR, 1986, CANCER RES, V46, P3990
[5]  
BALKWILL FR, 1987, CANCER RES, V47, P4755
[6]   CLINICAL-TRIALS OF A LOW-MOLECULAR-WEIGHT MATRIX METALLOPROTEINASE INHIBITOR IN CANCER [J].
BROWN, PD .
INHIBITION OF MATRIX METALLOPROTEINASES: THERAPEUTIC POTENTIAL, 1994, 732 :217-221
[7]   A cytokine profile of normal and malignant ovary [J].
Burke, F ;
Relf, M ;
Negus, R ;
Balkwill, F .
CYTOKINE, 1996, 8 (07) :578-585
[8]  
CHIRIVI RGS, 1994, INT J CANCER, V58, P406
[9]  
DAVIES B, 1993, CANCER RES, V53, P2087
[10]  
ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301